We are analyzing https://link.springer.com/article/10.1186/bcr2333.

Title:
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients | Breast Cancer Research
Description:
Introduction The persistence of circulating tumor cells (CTC) in breast cancer patients might be associated with stem cell like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors. Furthermore, these cells also may undergo phenotypic changes, known as epithelial-mesenchymal transition (EMT), which allows them to travel to the site of metastasis formation without getting affected by conventional treatment. Here we evaluated 226 blood samples of 39 metastatic breast cancer patients during a follow-up of palliative chemo-, antibody – or hormonal therapy for the expression of the stem cell marker ALDH1 and markers for EMT and correlated these findings with the presence of CTC and response to therapy. Methods 2 × 5 ml blood was analyzed for CTC with the AdnaTest BreastCancer (AdnaGen AG) for the detection of EpCAM, MUC-1 and HER2 transcripts. The recovered c-DNA was additionally multiplex tested for three EMT markers [Twist1, Akt2, PI3Kα] and separately for the tumor stem-cell markers ALDH1. The identification of EMT markers was considered positive if at least one marker was detected in the sample. Results 97% of 30 healthy donor samples investigated were negative for EMT and 95% for ALDH1 transcripts. CTC were detected in 69/226 (31%) cancer samples. In the CTC (+) group, 62% were positive for at least one of the EMT markers and 69% for ALDH1, respectively. In the CTC (-) group the percentages were 7% and 14%, respectively. In non-responders, EMT and ALDH1 expression was found in 62% and 44% of patients, in responders the rates were 10% and 5%, respectively. Conclusions Our data indicate that a major proportion of CTC of metastatic breast cancer patients shows EMT and tumor stem cell characteristics. Further studies are needed to prove whether these markers might serve as an indicator for therapy resistant tumor cell populations and, therefore, an inferior prognosis.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, breast, cells, tumor, patients, emt, stem, cell, markers, article, pubmed, google, scholar, aldh, metastatic, samples, ctcs, therapy, ctc, blood, cas, response, metastasis, treatment, expression, res, primary, akt, detected, data, circulating, positive, group, patient, marker, twist, analysis, nonresponders, responders, disease, phenotype, bone, figure, research, detection, study, marrow, pcr, ngμl, transition,

Topics {✒️}

sabine kasimir-bauer egfr/her2/pi3k/akt pathway article download pdf epithelial-mesenchymal transition markers phosphoinositide-dependent protein kinase-1 breast cancer-related therapies tumorigenic breast-cancer cells therapy-resistant cell populations pi3k/akt signaling kinases epithelial-mesenchymal transition epithelial mesenchymal transition tumor cell enrichment/selection signal-transduction pathways activated cell stem cell akt2 ser/thr kinase epidermal/mesenchymal transition full size image stem cell population cd44+/cd24-/low cells cancer stem cells epithelial-mesenchymal transitions stem cell properties stem cell preparations stem cell rev metastatic breast cancer ductal breast cancer stem cell markers tumor stem cells tumour progression metastatic cancer cells kasimir-bauer tumor cell growth breast cancer cells privacy choices/manage cookies authors’ original file epithelial cell homeostasis invasive breast carcinoma breast cancer res signal-transduction pathways exclude false-positive results cd44+/cd24- phenotype correlated breast cancer subtypes recurrent breast cancer emt multiplex rt-pcr negative prognostic impact early breast cancer circulating tumor cells human breast cancers article number r46 breast cancer patients

Questions {❓}

Polyak K: Breast cancer stem cells: a case of mistaken identity?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
         description:The persistence of circulating tumor cells (CTC) in breast cancer patients might be associated with stem cell like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors. Furthermore, these cells also may undergo phenotypic changes, known as epithelial-mesenchymal transition (EMT), which allows them to travel to the site of metastasis formation without getting affected by conventional treatment. Here we evaluated 226 blood samples of 39 metastatic breast cancer patients during a follow-up of palliative chemo-, antibody – or hormonal therapy for the expression of the stem cell marker ALDH1 and markers for EMT and correlated these findings with the presence of CTC and response to therapy. 2 × 5 ml blood was analyzed for CTC with the AdnaTest BreastCancer (AdnaGen AG) for the detection of EpCAM, MUC-1 and HER2 transcripts. The recovered c-DNA was additionally multiplex tested for three EMT markers [Twist1, Akt2, PI3Kα] and separately for the tumor stem-cell markers ALDH1. The identification of EMT markers was considered positive if at least one marker was detected in the sample. 97% of 30 healthy donor samples investigated were negative for EMT and 95% for ALDH1 transcripts. CTC were detected in 69/226 (31%) cancer samples. In the CTC (+) group, 62% were positive for at least one of the EMT markers and 69% for ALDH1, respectively. In the CTC (-) group the percentages were 7% and 14%, respectively. In non-responders, EMT and ALDH1 expression was found in 62% and 44% of patients, in responders the rates were 10% and 5%, respectively. Our data indicate that a major proportion of CTC of metastatic breast cancer patients shows EMT and tumor stem cell characteristics. Further studies are needed to prove whether these markers might serve as an indicator for therapy resistant tumor cell populations and, therefore, an inferior prognosis.
         datePublished:2009-07-09T00:00:00Z
         dateModified:2009-07-09T00:00:00Z
         pageStart:1
         pageEnd:9
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr2333
         keywords:
            Metastatic Breast Cancer
            Cancer Stem Cell
            Circulate Tumor Cell
            Metastatic Breast Cancer Patient
            Tumor Stem Cell
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2333/MediaObjects/13058_2009_2297_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2333/MediaObjects/13058_2009_2297_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2333/MediaObjects/13058_2009_2297_Fig3_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Bahriye Aktas
               affiliation:
                     name:University Hospital Essen, University of Duisburg-Essen
                     address:
                        name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mitra Tewes
               affiliation:
                     name:University Hospital Essen, University of Duisburg-Essen
                     address:
                        name:Department of Internal Medicine (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tanja Fehm
               affiliation:
                     name:University Hospital of Tuebingen
                     address:
                        name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Siegfried Hauch
               affiliation:
                     name:AdnaGenAG
                     address:
                        name:AdnaGenAG, Langenhagen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rainer Kimmig
               affiliation:
                     name:University Hospital Essen, University of Duisburg-Essen
                     address:
                        name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sabine Kasimir-Bauer
               affiliation:
                     name:University Hospital Essen, University of Duisburg-Essen
                     address:
                        name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
      description:The persistence of circulating tumor cells (CTC) in breast cancer patients might be associated with stem cell like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors. Furthermore, these cells also may undergo phenotypic changes, known as epithelial-mesenchymal transition (EMT), which allows them to travel to the site of metastasis formation without getting affected by conventional treatment. Here we evaluated 226 blood samples of 39 metastatic breast cancer patients during a follow-up of palliative chemo-, antibody – or hormonal therapy for the expression of the stem cell marker ALDH1 and markers for EMT and correlated these findings with the presence of CTC and response to therapy. 2 × 5 ml blood was analyzed for CTC with the AdnaTest BreastCancer (AdnaGen AG) for the detection of EpCAM, MUC-1 and HER2 transcripts. The recovered c-DNA was additionally multiplex tested for three EMT markers [Twist1, Akt2, PI3Kα] and separately for the tumor stem-cell markers ALDH1. The identification of EMT markers was considered positive if at least one marker was detected in the sample. 97% of 30 healthy donor samples investigated were negative for EMT and 95% for ALDH1 transcripts. CTC were detected in 69/226 (31%) cancer samples. In the CTC (+) group, 62% were positive for at least one of the EMT markers and 69% for ALDH1, respectively. In the CTC (-) group the percentages were 7% and 14%, respectively. In non-responders, EMT and ALDH1 expression was found in 62% and 44% of patients, in responders the rates were 10% and 5%, respectively. Our data indicate that a major proportion of CTC of metastatic breast cancer patients shows EMT and tumor stem cell characteristics. Further studies are needed to prove whether these markers might serve as an indicator for therapy resistant tumor cell populations and, therefore, an inferior prognosis.
      datePublished:2009-07-09T00:00:00Z
      dateModified:2009-07-09T00:00:00Z
      pageStart:1
      pageEnd:9
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr2333
      keywords:
         Metastatic Breast Cancer
         Cancer Stem Cell
         Circulate Tumor Cell
         Metastatic Breast Cancer Patient
         Tumor Stem Cell
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2333/MediaObjects/13058_2009_2297_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2333/MediaObjects/13058_2009_2297_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2333/MediaObjects/13058_2009_2297_Fig3_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Bahriye Aktas
            affiliation:
                  name:University Hospital Essen, University of Duisburg-Essen
                  address:
                     name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mitra Tewes
            affiliation:
                  name:University Hospital Essen, University of Duisburg-Essen
                  address:
                     name:Department of Internal Medicine (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tanja Fehm
            affiliation:
                  name:University Hospital of Tuebingen
                  address:
                     name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Siegfried Hauch
            affiliation:
                  name:AdnaGenAG
                  address:
                     name:AdnaGenAG, Langenhagen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rainer Kimmig
            affiliation:
                  name:University Hospital Essen, University of Duisburg-Essen
                  address:
                     name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sabine Kasimir-Bauer
            affiliation:
                  name:University Hospital Essen, University of Duisburg-Essen
                  address:
                     name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:11
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Hospital Essen, University of Duisburg-Essen
      address:
         name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
         type:PostalAddress
      name:University Hospital Essen, University of Duisburg-Essen
      address:
         name:Department of Internal Medicine (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
         type:PostalAddress
      name:University Hospital of Tuebingen
      address:
         name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
         type:PostalAddress
      name:AdnaGenAG
      address:
         name:AdnaGenAG, Langenhagen, Germany
         type:PostalAddress
      name:University Hospital Essen, University of Duisburg-Essen
      address:
         name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
         type:PostalAddress
      name:University Hospital Essen, University of Duisburg-Essen
      address:
         name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Bahriye Aktas
      affiliation:
            name:University Hospital Essen, University of Duisburg-Essen
            address:
               name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
               type:PostalAddress
            type:Organization
      name:Mitra Tewes
      affiliation:
            name:University Hospital Essen, University of Duisburg-Essen
            address:
               name:Department of Internal Medicine (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
               type:PostalAddress
            type:Organization
      name:Tanja Fehm
      affiliation:
            name:University Hospital of Tuebingen
            address:
               name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
               type:PostalAddress
            type:Organization
      name:Siegfried Hauch
      affiliation:
            name:AdnaGenAG
            address:
               name:AdnaGenAG, Langenhagen, Germany
               type:PostalAddress
            type:Organization
      name:Rainer Kimmig
      affiliation:
            name:University Hospital Essen, University of Duisburg-Essen
            address:
               name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
               type:PostalAddress
            type:Organization
      name:Sabine Kasimir-Bauer
      affiliation:
            name:University Hospital Essen, University of Duisburg-Essen
            address:
               name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
      name:Department of Internal Medicine (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
      name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
      name:AdnaGenAG, Langenhagen, Germany
      name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
      name:Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

External Links {🔗}(136)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.17s.

LINK . SPRINGER . COM {}